What You Should Know:
– Viome, a pioneer in microbiome health science and personalized health solutions, today announced a $25 million internal Series D with participation from Khosla Ventures, Bold Capital WRG Ventures, Marc Benioff, and more.
– This continued support from existing backers underscores their confidence in the company’s innovative approach and growth trajectory, reflected in its projected YoY increase.
Viome Appoints Kal Raman as COO to Accelerate Preventive Healthcare Innovations
Viome, a leading company in longevity and preventive healthcare, is advancing its mission to revolutionize early disease detection and preventative care through the appointment of Kal Raman as Chief Operating Officer (COO). Raman, known for his leadership roles at Amazon, Groupon, and Samsung, will drive the company’s expansion of diagnostic solutions aimed at combating chronic diseases, cancer, and aging.
With the increasing demand for advanced, personalized health solutions, Raman’s appointment comes at a pivotal time. The current healthcare model, where only 8% of Americans undergo routine preventive screenings and just 28% of patients are diagnosed at early stages, reflects the need for more proactive approaches to healthcare. Viome is well-positioned to address this gap by harnessing artificial intelligence and personalized solutions to enhance preventive care.
Raman’s extensive experience scaling business growth, enhancing automation, and driving strategic initiatives will support Viome’s efforts to introduce innovative diagnostic tests. The company has already set new standards in early cancer detection with its CancerDetect™ test, which boasts 90% sensitivity and 95% specificity. Building on this success, Viome plans to expand its diagnostics beyond oral and throat cancer to include gut health and other critical areas in the coming year. These efforts are further strengthened by the FDA Breakthrough Device Designation, which allows for accelerated review of their life-saving technologies.
Viome’s unique approach integrates groundbreaking RNA sequencing with artificial intelligence, analyzing epigenetic biomarkers to provide personalized nutritional guidance and microbiome health products. To date, the company has empowered over half a million users, offering AI-driven health insights to improve lifespan and well-being.
Kal Raman’s appointment underscores Viome’s commitment to its goal of making illness optional. By focusing on early detection and personalized health solutions, the company seeks to empower individuals to proactively manage their health, while also ensuring customer satisfaction and innovation remain top priorities.
“What attracted me to Viome was its mission to have a meaningful impact on the health of individuals. Viome is a true innovator and pioneer in the health space, being one of the first to recognize the critical importance of preventative measures. This is evident by the success of its microbiome tests, which have already helped thousands take control of their health through personalized insights and recommendations. I am excited to join a team that is at the forefront of transforming healthcare and am eager to help Viome achieve the same level of success in the diagnostics space”, said Kal Raman.
